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Abstract
Interferon Regulatory Factor-3 (IRF-3) plays a central role in the induction of interferon (IFN) production and
succeeding interferon-stimulated genes (ISG) expression en route for restraining hepatitis C virus (HCV) infection.
Here, we established a stable Huh7.5-IRF3ER cell line expressing a fusion protein of IRF-3 and mouse estrogen
receptor (ER) to examine IFN production and anti-HCV effects of IRF-3 in retinoic acid inducible-gene-I (RIG-I)
deficient Huh 7.5 cells. Homodimerization of the IRF-3ER fusion protein was detected by Western blotting after
treatment with the estrogen receptor agonist 4-hydrotamoxifen (4-HT) in Huh7.5-IRF3ER cells. Expression of IFN-a,
IFN-b, and their inhibitory effects on HCV replication were demonstrated by real-time polymerase chain reaction
(PCR). Peak expression of IFN-a and IFN-b was achieved 24-hours post 4-HT treatment, coinciding with the
appearance of phosphorylated signal transducer and activator of transcription (STAT) proteins. Additionally, HCV
viral replication declined in time-dependent fashion. In previous studies, a novel IFN-mediated pathway regulating
expression of 1-8U and heterogeneous nuclear ribonucleoprotein M (hnRNP M) inhibited HCV internal ribosomal
entry site (IRES)-dependent translation. When expression of ISGs such as 1-8U and hnRNP M were measured in 4-
HT-treated Huh7.5-IRF3ER cells, both genes were positively regulated by activation of the IRF-3ER fusion protein. In
conclusion, the anti-HCV effects of IRF-3ER homodimerization inhibited HCV RNA replication as well as HCV IRES-
dependent translation in Huh7.5-IRF3ER cells. The results of this study indicate that IRF-3ER homodimerization is a
key step to restore IFN expression in Huh7.5-IRF3ER cells and in achieving its anti-HCV effects.
Introduction
Hepatitis C virus infection causes chronic liver diseases,
cirrhosis, and hepatic cellular carcinoma (HCC) with 170
million people worldwide and 4 million people in the
United States reportedly infected (CDC, 1998). In addi-
tion to its global health problem [1], future projections
suggest that HCV related mortality will increase 2-3-fold
over the next decade [2] with more than 180 billion US
dollars estimated total social economic cost in the United
States [3]. The standard treatment of chronic HCV is
anti-viral therapy with IFN and ribavirin (RBV) but no
HCV vaccine available. Despite additional chemothera-
peutics is on hand for treatment of genotype I HCV
patients recently, the anti-viral mechanisms of IFN-based
therapies are not well defined, but most likely involve the
activation of host innate immunity to limit HCV
replication.
During microbial infection, the recognition of microbial
components is mediated by host-specific cellular patho-
gen-recognition receptors (PPRs). PPRs are members of
the toll-like receptor (TLRs) family and are localized either
to cellular plasma (TLR4 for lipopolysaccharide (LPS) and
viral envelops) or endosomal membranes (TLR3 for
dsRNA, TLR7/8 for ssRNA and TLR9 for DNA [4-7]).
Conversely, intracellular dsRNA is also recognized by the
RIG-I cytosolic RNA helicase or melanoma differentiation
associated gene (MDA)-5 [8]. RIG-I RNA helicase was
found to be an essential mediator of anti-HCV effects due
to its binding to un-capped 5’-end and 3’-end HCV
dsRNA, triggering host innate immunity [9].
IFNs bind to the IFN-a/b receptor (IFNAR) in either an
autocrine and/or paracrine manner to initiate a positive
feedback loop that results in the production of more type I
IFNs. IFNARs trigger the activation of the JAK/STAT
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transcription factors associated with IRF-9 to form a het-
erotrimeric complex, IFN-stimulated gene factor 3
(ISGF3), initiating the transcription of IFN-stimulated
genes (ISGs) and inhibiting the different stages of virus
replication and eliciting an anti-viral state in the host
[10,11]. During HCV infection, these anti-viral effects
include the inhibitory effects on host and HCV translation
[12,13], regulation of cellular proliferation and apoptosis
[14], regulation of adaptive immunity [15,16], and recruit-
ment of NK cells to the site of infection [17,18] to clear
HCV infection by inhibiting HCV gene expression and
HCV replication. Patients with cleared HCV infection
without IFN-based treatment provides strong evidence for
the host innate immune response during acute HCV infec-
tion [19,20].
In order to study the direct anti-HCV response of IRF-3
activation, an inducible Huh7.5-IRF3ER cell line was estab-
lished in RIG-I deficient Huh 7.5 cells that allow IRF-3
protein homodimer formation in a cytokine/receptor-inde-
pendent fashion. Huh 7.5 cells are a highly adapted and
poorly differentiated hepatoma cell line that lacks the ability
to produce detectable interferon-a/b when infected with
HCV JFH-1 virus [21]. Therefore, Huh7.5-IRF3ER cells is
an adequate system to study the downstream molecular
events of IRF-3 activation and establishment of a subse-
quent anti-HCV state without RIG-I activation in Huh 7.5
cells.
Materials and Methods
Plasmids
A mammalian expression vector, pTIRF3ER, was con-
structed as a fusion protein of the IRF3 gene (51.6 Kd)
[22] and C-terminal sequences of the mouse estrogen
receptor (310 a.a.) [23] in the pEF6/V5-His TOPO
® TA
vector (Invitrogen, Carlsbad, CA). The plasmid pJFH-1
contains a full-length HCV genomic cDNA [24]. The plas-
mid pRL-HL is a dicistronic construct that mediates Cap-
dependent and HCV IRES-dependent translation [25].
Synthetic 4-hydroxytamoxifen (4-HT) was purchased from
Sigma (Saint Louis, MO) and dissolved in ethanol as a
5 mM stock solution.
Cell lines
Human hepatoma Huh 7.5 cells [26] were grown in Dul-
becco’s modified Eagle’s medium (Invitrogen). To establish
the Huh7.5-IRF3ER cell line, Huh 7.5 cells were trans-
fected with the plasmid pTIRF3ER and Lipofectin (Invitro-
gen). Blasticidin (Invitrogen) (10 μg/ml) was used for the
clone selection 24-hours after transfection. Medium was
changed every 3 days with fresh Blasticidin until day 14, at
which time, positive clones were propagated. The clones
were amplified and IRF-3ER dimer formation was mea-
sured by Western blotting after 4-HT treatment.
Detection of IRF-3ER dimers, p-STAT1 (S727), p-STAT3
(Y705), and 1-8U protein by Western blotting
Huh7.5-IRF3ER cell monolayers were washed in phos-
phate buffered saline (PBS) post 4-HT treatment with pro-
tease inhibitor cocktail (Sigma). Preparation of Huh7.5-
IRF3ER cell lysates was performed as reported previously
[27]. Cellular lysates were separated by sodium dodecylsul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) (6%
gel for IRF-3ER dimers; 8% gel for p-STAT1 (S727) and
p-STAT3 (Y705)). Western blotting was carried out as
previously reported [27] with antibodies for actin (Santz
Cruz Biotechnology, Inc., Santa Cruz, CA), p-STAT3
(Y705) (Cell Signaling, Boston, MA), p-STAT3 (Y705)
(Cell Signaling), and STAT1 (Santz Cruz). Western blot-
ting of STAT1 and STAT3 proteins were performed with
the same PVDF membrane used for detection of p-STAT1
(S727) and p-STAT3 (Y705) after stripping the blot (Bio-
rad stripping buffer).
HCV JFH-1 stocks and HCV infection
Preparation and titration of HCV JFH-1 virus was reported
previously [24]. For examining anti-HCV effects, Huh7.5-
IRF3ER cells were incubated with 0.5 MOI JFH-1 HCV for
14 days to achieve fully infected Huh7.5-IRF3ER mono-
layer cells [28]. The Huh7.5-IRF3ER cells were then trea-
ted with 4-HT for 72, 48 and 24 hours prior to collecting
total cellular RNA. Huh7.5-IRF3ER cells without 4-HT
treatment for 72 hours were used as control. Total RNA
was isolated for detecting HCV RNA by real-time PCR.
Detection of IFN-a and IFN-b in Huh7.5-IRF3ER cells
Huh7.5-IRF3ER cells were treated with 4-HT for 72, 48,
and 24 hours prior to collecting cellular lysates. Control is
Huh7.5-IRF3ER cells that did not receive 4-HT treatment
for 72 hours. Total cellular RNA was isolated for detecting
IFN-a or IFN-b RNA by real-time PCR.
Real-Time PCR assay
Total cellular RNA was isolated from infected Huh7.5-
IRF3ER monolayers by Trizol (Invitrogen). First-strand
cDNA were synthesized from 1 μg total cellular RNA by
reverse transcription (20 μl of reaction volume). Super-
script II (200 U reverse transcriptase per reaction) and a
RT-PCR kit (Invitrogen) was used to prime with oligo
(dT) 12-18 for first-strand synthesis according to the man-
ufacturer’s instructions. Taqman primers were obtained
from Applied BioSystems. Reactions were conducted in a
96-well MyiQ cycler (Bio-Rad, Hercules, CA). Fluores-
cence was monitored during every PCR cycle at the
annealing step. The primers for HCV JFH-1 are: forward,
5’-CGGAATTGCCGGGAAGAC-3’;r e v e r s e ,5 ’-CAAA
TGGCCGGGCATAG AG-3’;F A Mp r o b e ,5 ’-CTTTC
TTGGATAAACCC-3’.T h ep r i m e r sf o rI F N - a are: for-
ward, 5’- GGGATGAGGACCTCCTAGACAAATT-3’;
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FAM probe, 5’- CTGCACCGAACTCTAC-3’.T h ep r i -
mers for IFN-b are: forward, 5’-TGGCTGGAATGAGAC-
TATTGTTGAG-3’; reverse, 5’-CAGGACTGTCTTCA
GATGG-TTTATCT-3’;F A Mp r o b e ,5 ’-CCTCCTGGC
TAATGTC-3’. GADPH primers were purchased from the
Applied Biosystems. PCR was performed with the follow-
i n gc o n d i t i o n s :5 0 ° C ,2m i n ;9 5 ° C ,1 0m i n ;( 9 5 ° C ,1 5 s ;
60°C, 1 min) for 40 cycles. Relative RNA level indicates
statistical quantification of altered RNA levels from these
cellular lysates with different primers. Samples were run in
triplicate and the results were analyzed using the Bio-Rad
iQ5 software; means ± the standard error of the mean are
shown.
Luciferase assays
Huh7.5-IRF3ER cells were cultured in 6-well plates and
transfected with the plasmid pRL-HL and lipofectamine
2000 (Invitrogen). After 24-hours of transfection, Huh7.5-
IRF3ER cells were treated with 4-HT for 96, 72, and
48 hours prior to preparing cell lysates. Control Huh7.5-
IRF3ER cells were incubated for 96 hours in the absence
of 4-HT. All samples were analyzed for luciferase activity
using the Dual-Luciferase Reporter Assay System Kit (Pro-
mega, Madison, WI) in triplicate. The translation effi-
ciency was calculated as a proportion of control (100%).
Statistical analysis
Different cellular lysates were collected for analysis of
luciferase activity or relative RNA level from Huh7.5-
IRF3ER cells with special treatment. Results of these
studies are expressed as means ± standard deviation
(SD).
Results
Dimerization of IRF-3ER fusion protein induced by 4-HT in
Huh7.5-IRF3ER cells
Activation of IRF-3 or IRF-7 is a critical step during virus
infection, promoting the most potent type I IFN produc-
tion. Previous studies showed the constitutively active
forms (serines replaced by phosphomimetic aspartate
amino acids) of human IRF-3 protein exerts the ability to
modulate the apoptotic and anti-tumor properties after
being delivered by recombinant adenovirus into macro-
phages [22]. In our studies, a fusion protein of IRF-3 and
C-terminal sequences (310 a.a.) of mouse estrogen recep-
tor was used to establish the stable Huh7.5-IRF3ER cell
line. In previous studies, mouse estrogen receptor was
effective at inducing dimerization of STAT1 and STAT3
fusion proteins after 4-HT treatment [27,23,29]. In these
studies from us and others, 4-HT was titrated to a con-
centration of 1 μM that achieved the highest expression
of STAT1ER and STAT3ER dimerization and the stron-
gest inhibitory effects on HCV RNA replication [23,29].
In our studies, 4-HT-treatment alone was also demon-
strated to have no anti-HCV effects [23]. In this study,
similar sequences from the mouse ER C-terminal domain
were fused to the C-terminus of the IRF-3 gene. In Figure
1, Western blotting with anti-IRF-3 antibody was used to
detect the IRF-3 as well as the IRF-3ER monomer and
dimer proteins. Lane 1 shows endogenous IRF3 protein
(56.1 kd) but no IRF-3ER fusion protein in Huh 7.5 cells
treated with 4-HT. Lane 2 shows both IRF-3 and IRF-
3ER (monomer) (90 kd) in Huh7.5-IRF3ER cells without
4-HT treatment. Lane 3 shows that 4-HT treatment of
Huh7.5-IRF3ER cells induces IRF-3ER fusion protein
dimer formation (180 kd) in addition to IRF-3 protein
and IRF-3ER monomers. The density of IRF-3ER dimers
was less than the density of IRF-3ER monomers (Figure
1, lane 3), which could be explained by the denaturing
conditions used in the analysis as suggested in our pre-
vious report, including SDS-polyacrylamide gel electro-
phoresis, RIPA lysis buffer, and boiling during Western
blotting [27]. Interestingly, a small amount of IRF-3ER
dimer formation was detected in Huh7.5-IRF3ER cells
without 4-HT treatment (Figure 1, lane 2). This may be
due either to auto-dimerization of IRF-3ER or dimer for-
mation induced by trace estrogen in the tissue culture
medium. Multiple forms of the IRF-3ER fusion protein
were also detected (Figure 1, lane 3). Our data indicates
the IRF-3ER fusion protein approach is an effective
means to achieve IRF-3 homodimerization with 4-HT
treatment.
Expression of IFNs after activation of the IRF-3ER fusion
protein
Due to deficient RIG-I gene function in Huh 7.5 cells,
virus infection will not lead to IRF-3 activation and IFN
Figure 1 Dimerization of the IRF-3ER fusion protein in Huh7.5-
IRF3ER cell line. Huh7.5-IRF3ER and Huh 7.5 cells were treated with
or without 4-HT. Total cellular protein was extracted and analyzed
for Western blotting with anti-IRF3 antibody. Lane 1, Huh7.5 cells
treated with 4-HT. Lane 2, Huh7.5-IRF3ER cells without 4-HT
treatment. Lane 3, Huh7.5-IRF3ER cells treated with 4-HT.
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gene function against HCV infection by establishing a
stable Huh7.5-IRF3ER cell line. Fusion proteins of STAT1
and STAT3 with the mouse estrogen receptor provided a
useful means to study dimerization of those proteins and
resulting in anti-HCV status [27,23]. In this study, the
IRF-3 gene was fused with same C-terminal sequences of
mouse estrogen receptor as reported [27,23] for inducing
IRF-3ER dimerization by 4-HT treatment. Expression of
type I IFNs (a and b) was examined after 4-HT treatment
by real-time PCR. In Figure 2A and 2B, IFN-a and IFN-b
increased and peaked 24 hours after 4-HT induction. To
further demonstrate the biological activities of IFN-a and
IFN-b after IRF-3ER dimerization, Western blotting was
used to detect phosphorylated STAT1 and STAT3. In
Figure 3A, phosphorylated STAT1 was detected with an
antibody against STAT1 (S727) in Huh 7.5 and Huh7.5-
IRF3ER cells (Figure 3A, lane 1, 2, 3). Different amounts
of phosphorylated STAT1 were observed in both Huh 7.5
cells and Huh7.5-IRF3ER cells (Figure 3A, lane 1 and 2).
There were no appreciable time-dependent differences in
phosphorylated STAT1 in Huh7.5-IRF3ER cells with or
without 4-HT treatment (Figure 3A, lane 2 to 9). This
observation is consistent with the auto-dimerization of
IRF-3ER fusion protein (Figure 1, lane 2) to produce IFNs
(controls of Figure 2A and 2B). In Figure 3B, phosphory-
lated STAT3 was examined; there was no difference
between Huh 7.5, Huh7.5-IRF3ER cells with or without 4-
HT treatment (Figure 3B, lane 1 to 9). This phenomenon
could be explained by the constant activation of IRF-7 to
induce expression of IFN-a which activates the type I IFN
pathway through STAT3 phosphorylation [10]. Total
STAT1 and STAT3 proteins was used as internal controls
and demonstrated no differences with or without 4-HT
treatment on Huh7.5-IRF3ER cells or Huh 7.5 cells (Figure
3A and 3B, lane 1 to 9).
Inhibitory effects of IRF-3ER dimerization on HCV JFH-1
virus replication
Huh7.5-IRF3ER cells were further examined for its inhi-
bitory effects on HCV JFH-1 viral replication after 4-HT
treatment. Huh7.5-IRF3ER cells were inoculated with
0 . 5M O Io fJ F H - 1v i r u ss t o c ka n dc u l t u r e df o r1 4d a y s
to achieve full HCV JFH-1 infected Huh7.5-IRF3ER cell
state. The infected Huh7.5-IRF3ER cells were treated
with 4-HT (1 μM) at the indicated times and harvested
at the last-sample collection point for analysis of HCV
RNA by real-time PCR. The infected Huh7.5-IRF3ER
cells were used as control without 4-HT treatment for
72 hours. In Figure 4A, HCV JFH-1 replication
decreased to 50% of control after 24 hours of 4-HT
treatment. This data indicates that IRF-3ER dimerization
after 4-HT treatment has inhibitory effects on HCV
JFH-1 replication and was correlated with the produc-
tion of IFN-a and IFN-b (Figure 2A and 2B). To further
separate HCV JFH-1 viral RNA replication and viral
translation, the plasmid pRL-HL, containing Cap-depen-
dent Renilla luciferase translation and HCV IRES-
mediated Firefly luciferase translation start sites, was
used in this study [25]. After transfection of pRL-HL,
Huh7.5-IRF3ER cell lysates were harvested at various
times after 4-HT treatment for analysis of luciferase
activity. In Figure 4B, both Cap-dependent and HCV
IRES-mediated translation was reduced in Huh7.5-
IRF3ER cells after 4-HT treatment in a time-dependent
fashion. This data shows strong evidence that activation
of the IRF-3ER fusion protein not only inhibits JFH-1
viral RNA replication but also inhibits Cap-dependent
and HCV IRES-mediated translation.
Figure 2 Expression of IFN-a and IFN-b in Huh7.5-IRF3ER cells
with 4-HT treatment. Huh7.5-IRF3ER cells were treated with 4-HT
for 72, 48, and 24 hours prior to collecting cellular lysates. Control is
Huh7.5-IRF3ER cells that did not receive 4-HT treatment for 72
hours. Total cellular RNA was isolated for detecting IFN-a or IFN-b
RNA by real-time PCR. A. Expression of IFN-a in Huh7.5-IRF3ER cells.
B. Expression of IFN-b in Huh7.5-IRF3ER cells.
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All of the IFN types activate JAK/STAT pathways, regu-
lating the expression of over 300 ISGs in order to
achieve their anti-viral effects [30]. In our previous stu-
dies, we demonstrated a novel pathway by which IFN
inhibits HCV IRES-mediated translation through up-reg-
ulating 1-8U gene expression [27] and down-regulating
expression of the hnRNP M gene (unpublished data). In
this study, we measured 1-8U and hnRNP M expression
in Huh7.5-IRF3ER cells with and without 4-HT treat-
m e n t .I nF i g u r e5 A ,t h e1 - 8 Up r o t e i nw a sd e t e c t e db y
Western blotting and was up-regulated in Huh7.5-
IRF3ER cells after 4-HT treatment. Due to auto-dimeri-
zation of IRF-3ER fusion protein in Huh7.5-IRF3ER
cells, the fold-induction of 1-8U protein (Figure 5A,
lane 1, 2, and 3) is not as robust as described in our
previous report in which the STAT1 gene was activated
[27]. Real-time quantitative reverse-transcription PCR
was used to detect and measure hnRNP M mRNA
expression in Huh7.5-IRF3ER cells. After 4-HT treat-
ment, hnRNP M mRNA levels were down-regulated in a
time-dependent fashion (Figure 5B). This data confirms
that activation of the IRF-3ER fusion protein triggers a
cellular anti-HCV state through inducing IFNs produc-
tion and regulating ISG expression.
Discussion
Host immunity, including innate immunity and adaptive
immunity, is an important and complicated system dedi-
cated to the task of defending the host from microbial
infection and cancer development. Innate immunity pro-
vides an immediate (first line) reply to a microbial infec-
tion, specifically for viral infections, while also controlling
the later antigen-specific adaptive response. A key aspect
of the antiviral innate immune response is the synthesis
and secretion of type I INFs (a and b), which exhibit
Figure 3 Phosophorylation of STAT1 and STAT3 proteins in
Huh7.5-IRF3ER cells. Huh 7.5 and Huh7.5-IRF3ER cells were used to
detect phosophorylation of STAT1 and STAT3 proteins. Huh7.5-
IRF3ER cells were treated without or with 4-HT to induce IRF-3ER
dimerization. Total protein was extracted and analyzed by Western
blotting with anti-p-STAT1 (S727) antibody, anti-STAT1 antibody
(Figure A); anti-p-STAT3 (Y705) antibody and anti-STAT3 antibody
(Figure B), respectively. Lane 1, Huh7.5 cells with 4-HT; lane 2,
Huh7.5-IRF3ER without 4-HT; lane 3 to lane 9, Huh7.5-IRF3ER with 4-
HT induction from 0.5 to 72 hours. Figure 4 Anti-HCV effects of the IRF-3ER fusion protein in
Huh7.5-IRF3ER cells. A. Inhibitory effects of IRF-3ER
dimerization on HCV RNA replication. Huh7.5-IRF3ER cells were
inoculated with HCV JFH-1 stock at a MOI 0.5 for 14 days and then
4-HT (1 μM) was added at 72, 48, and 24 hours prior to end-point
for sample collection. Control indicates the JFH-1 infected Huh7.5-
STAT1ER cells without 4-HT treatment for 72 hours. HCV JFH-1 RNA
levels were measured by quantitative real-time PCR in triplicate.
Relative JFH-1RNA level was calculated as proportion of control (1.0).
The data is presented after normalization with an internal GAPDH
control. The error bars indicate the variation present in three
independent assays. B. Inhibitory effects of IRF-3ER dimerization
on HCV IRES-mediated translation. Huh7.5-IRF3ER cells were
transfected with the plasmid pRL-HL. After 24 hours of incubation at
37°C and 5% CO2, transfected Huh7.5-STAT1ER cells were treated
with 4-HT for 48, 72, and 96 hours for analyses of luciferase activity.
Control Huh7.5-IRF3ER cells received the pRL-HL cDNA plasmid but
did not receive 4-HT treatment. Translation efficiency for each
sample was calculated as proportion of control (100%). The error
bars indicate the variation of three independent assays.
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tions. Two key steps are required to elicit an effective
antiviral innate immune response: a. detection of the
invading virus by immune system receptors; b. initiation
of protein signaling cascades that regulate the synthesis
of IFNs. Viruses are highly infectious pathogens that
depend on host cellular machinery for survival and repli-
cation. Most viral infections, like the common cold
caused by Rhinoviruses, are efficiently resolved by the
host innate and adaptive immune system. For other viral
infections, such as chronic hepatitis B or C viral infection,
the host innate and adaptive immunity response is unable
to clear them effectively and they become persistent
infections. Several families of PPRs have been demon-
strated to inspect the cellular micro-environment for
microbial infection to target the pathogen-associated
molecular patterns (PAMPs), a conserved structural moi-
ety essential for microbial survival. Toll-like receptors
(TLRs 3, 4, 7, 8, and 9) in addition to RIG-I are major
PPRs that recognize different types of virally-derived
nucleic acids or intracellular dsRNA to initiate signaling
cascades leading to production of type I IFNs (details in
reviews [11,31,32]). The mechanisms by which different
viruses induce a unique IFN-mediated antiviral response
appear to require selective activation of members of the
IRF family of proteins (IRF-1 to IRF-9). Thus far, IRF-3
and IRF-7 have been shown to be major regulators of
IFN gene expression [33,10].
T h et y p eII F N s ,r e p r e s e n t ed by multiple subtypes of
IFN-a in addition to one subtype IFN-b,a r ek e yc y t o -
kines in this process, mounting an immediate antiviral
response as well as adaptive immunity. IFN-mediated
anti-viral effects are carried out using different mechan-
isms that are dependent on the type of viral infection, but
these anti-viral effects are all dependent on IRF-3 activa-
tion [35,34,33,21,7]. Activation of IRF-3 proteins appears
to recruit the Tank Binding Kinase 1 (TBK1) and inhibi-
tor of IB-related kinase epsilon (IKKε) [7] through their
interaction with the RIG-I RNA helicase [36], resulting in
phosphorylation of IRF-3, its dimerization, nuclear trans-
location, and transcriptional activation through binding
to IFN-stimulated response elements (ISREs) [37]. Acti-
vated IRF-3 interacts with nuclear factor-B (NF-B) and
transcriptional factor-2/c-Jun to form a transcriptionally
active enhanceosome complex on IFNA1 and IFNB gene
promoters.
In our studies, we utilized an IRF-3/mouse ER fusion
protein expressing plasmid in order to achieve IRF-3ER
activation in a cytokine/receptor-independent fashion.
Our results demonstrated that IRF-3ER homodimers
(Figure 1, lane 3) triggered the downstream pathways to
produce IFN-a and IFN-b (Figure 2A and 2B). The anti-
HCV effects, induced by 4-HT in Huh7.5-IRF3ER cells,
were achieved by decreasing HCV RNA replication and
HCV IRES-mediated translation. This is consistent with
our previous studies which achieved activation of STAT1/
and STAT3/mouse ER fusion proteins. Activation of the
IRF-3ER fusion protein by 4-HT treatment provides
strong evidence that this is necessary and sufficient to
increase IFN-a and IFN-b expression in Huh7.5-IRF3ER
cells (Figure 2A and 2B). Our data showing that IRF-3ER
activation triggers the downstream pathway, activating the
JAK/STAT pathway and regulating ISG expression. Detec-
tion of p-STAT1 (S727) and p-STAT3 (Y705) in Huh7.5-
IRF3ER cells provides a strong evidence for activation of
Jak/STATs pathway by IFNs (Figure 3A and 3B). Although
Figure 5 Expression of 1-8U and hnRNP M genes in Huh7.5-
IRF3ER cells. A. Gene expression of 1-8U in Huh7.5-IRF3ER cells.
Huh7.5-IRF3ER cell lysates were harvested at 0, 24, and 48 hours
after adding 4-HT to induce IRF-3ER dimerization. Total protein was
extracted and analyzed by Western blotting with an anti-1-8U
antibody. Lane 1, Huh7.5-IRF-3ER cell lysate from cells treated with
4-HT at 0 hours; lane 2 and 3, Huh7.5-STAT1ER cell lysates from cells
treated with 4-HT for 24 and 48 hours. Actin protein was used as an
internal control. B. Expression of hnRNP M in Huh7.5-IRF3ER
cells. Huh7.5-IRF3ER cells were treated by 4-HT (1 μM) for 72, 48,
and 24 hours prior to collecting cell lysates. Control is mock
treatment of 4-HT for 72 hours. Expression of hnRNPM and GAPDH
(used as internal control) mRNA was measured using Taqman
primers from Applied Biosystems in triplicate. Relative hnRNP M
RNA levels were calculated as a proportion of the control (1.0).
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not been well defined, recent studies suggest that IFNs
have a great impact on HCV replication by interrupting
HCV IRES-mediated translation [38,12]. Clinical data con-
firmed these findings in a study of HCV IRES-mediated
translation in chronic HCV patients receiving IFN treat-
ment, in which the efficiency of HCV IRES-mediated
translation was reduced in IFN-treated HCV patients
[39,40]. In our study, the inhibitory effects of HCV RNA
replication and HCV IRES-mediated translation were con-
firmed in Huh7.5-IRF3ER cells after treatment with 4-HT
(Figure 4A and 4B).
Here, we present data demonstrating that activation of
the IRF-3 gene restores IFN production in RIG-I defi-
cient Huh 7.5 cells. The anti-HCV effects were achieved
in Huh7.5-IRF3ER cells by decreasing both HCV RNA
replication and HCV IRES-mediated translation.
Recently, two new genes, 1-8U and hnRNP M, were iso-
lated in our studies due to their ability to modulate cel-
lular Cap-dependent and HCV IRES-mediated
translation and regulated by STAT1 pathway activation.
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